BioTech Health X

In a shocking failure, Virios Therapeutics announced this morning pre-market that topline results from its FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 (“HSV-1”)) study of oral IMC-1 for the treatment of fibromyalgia did not achieve statistical significance.

Since market open, the stock price has dropped a massive 70% from $8.77 at market close on Friday, September 16th. NASDAQ: VIRI is currently trading at $2.58 as of publication wiping out over $50 Million in company market cap and valuation.

Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results Virios Therapeutics FORTRESS Fibromyalgia Phase 2 Trial did NOT achieve statistical significance dropping stock 70% erasing $50 Million in market cap.